TABA: Tools for the site-specific labeling and immobilization of antibodies for immunoassays

摘要：AlphaThera继续大规模商业化其部位特异性抗体结合产品，并遇到了 欢迎美国和世界各地消费者感兴趣的迹象，销售在几个国家和持续的客户咨询。 然而，与扩展和商业化相关的不断增加的费用促使我们探索更多的资金来源。这个 NIH/SBIR为支持第一阶段/第二阶段赠款而提供的Taba基金是使AlphaThera能够 继续朝着规模化商业化成功的快车道前进。TABA资金将分配给#年的三个主要类别 支持我们的商业化：多渠道营销；战略合作伙伴发展和知识产权保护。

Summary: AlphaThera continues to scale commercialization of its site-specific antibody conjugation products and has encountered welcoming signs of consumer interest across the US and the world, with sales in several countries and continued customer inquiries. However, increasing expenses associated with scaling and commercialization have led us to explore additional sources of funds. The TABA funds offered by the NIH/SBIR to support Phase I/Phase II grants are an ideal source of funding to enable AlphaThera to continue on its fast-track towards scaled commercialization success. TABA funding will be allocated toward three major categories in support of our commercialization: Multi-channel marketing; Strategic partner development and IP protection.